News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Email Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go Advanced Search Keywords Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Mar 11, 2009 Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results Mar 10, 2009 Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND Feb 26, 2009 Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call Feb 12, 2009 Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million Jan 21, 2009 Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants Dec 26, 2008 Insmed to Appeal Delisting Notification From Nasdaq Dec 23, 2008 Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule Nov 25, 2008 Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference Nov 18, 2008 Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation Nov 10, 2008 Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs Show 5102550100 per page«1…42434445464748…70» Stay In The Loop Want to stay up to date on our news, events, and filings? Set up your email alerts. Sign Up View the latest Insmed Investor Presentation Download